Literature DB >> 6508978

Estimation of gentamicin clearance and volume of distribution in neonates and young children.

A W Kelman, A H Thomson, B Whiting, S M Bryson, D A Steedman, G E Mawer, L A Samba-Donga.   

Abstract

Gentamicin therapy should be guided by serum level monitoring in all age groups, dosage adjustments depending on age related changes in pharmacokinetics. Population data analysed from two centres (43 infants from Glasgow and 100 infants and children from Manchester) by the computer program NONMEM showed that volume of distribution was related to body weight by a proportionality factor that decreased from the region of 0.41-0.46 l/kg in children less than 3 months to 0.25-0.32 l/kg in older children, a value which merges with that accepted for adults (0.25 l/kg). In both young and older children, clearance was also found to be dependent on body weight. Renal function (creatinine concentrations) provided no further explanatory power. When these results were used prospectively to forecast gentamicin concentrations with a Bayesian kinetic parameter estimation program, trough concentrations were more precisely predicted than peaks when a single concentration measurement was used. In clinical practice, however, two concentration measurements are usually routinely available and these should lead to greater precision of both peak and trough predictions. These results have been incorporated into a simple nomogram which can be used to determine a dose of gentamicin which will achieve target peak concentrations in infants, assuming that troughs should not exceed 2 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508978      PMCID: PMC1463552          DOI: 10.1111/j.1365-2125.1984.tb02530.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.

Authors:  L B Sheiner; H Halkin; C Peck; B Rosenberg; K L Melmon
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Factors influencing the therapeutic response to gentamicin treatment in children [proceedings].

Authors:  A Ashurst; I B Houston; G E Mawer; L Sambo-Donga
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

4.  Gentamicin: toxicity in perspective.

Authors:  W L Hewitt
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

5.  Gentamicin in the neonatal period.

Authors:  G H McCracken; L G Jones
Journal:  Am J Dis Child       Date:  1970-12

6.  Pharmacokinetics of gentamicin in very low birth weight preterm infants.

Authors:  K W Hindmarsh; R L Nation; G L Williams; E John; J N French
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  Gentamicin dosage in preterm and term neonates.

Authors:  B M Assael; V Gianni; A Marini; P Peneff; F Sereni
Journal:  Arch Dis Child       Date:  1977-11       Impact factor: 3.791

Review 9.  Tobramycin sulfate: a summary of worldwide experience from clinical trials.

Authors:  C L Bendush; R Weber
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

10.  Two-compartment gentamicin pharmacokinetics in premature neonates: a comparison to adults with decreased glomerular filtration rates.

Authors:  D B Haughey; D M Hilligoss; A Grassi; J J Schentag
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

View more
  23 in total

1.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 3.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Population pharmacokinetics: theory and practice.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

6.  Evaluation of population (NONMEM) pharmacokinetic parameter estimates.

Authors:  S Vozeh; P O Maitre; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

7.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

8.  Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients.

Authors:  E Hassan; J D Ober
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 9.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

10.  Population pharmacokinetics of gentamicin in South African newborns.

Authors:  J H Botha; M J du Preez; M Adhikari
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.